<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The escalating pandemic of the acquired <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> disease in sub-Saharan Africa is associated with an increasing incidence of the <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> where evidence shows that highly active retroviral therapy can reconstitute immunologic competence and, at least in some groups exemplified by <z:hpo ids='HP_0100726'>Kaposi's sarcoma</z:hpo>, result in an outcome comparable to uninfected controls </plain></SENT>
<SENT sid="1" pm="."><plain>Paradoxically other subtypes are less responsive exemplified by Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and <z:e sem="disease" ids="C1334815" disease_type="Neoplastic Process" abbrv="">multicentric Castleman's disease</z:e>, where they are localised and may present after starting treatment </plain></SENT>
<SENT sid="2" pm="."><plain>This association provides a model to test the concept that pathogenesis may reflect an aberrant response to antigens including human herpesvirus-8 thereby renewing focus on proactive inclusion of anti-<z:e sem="disease" ids="C0019340" disease_type="Disease or Syndrome" abbrv="">herpes</z:e> drugs with conventional treatment for retrovirus particularly prior to initiating chemotherapy </plain></SENT>
</text></document>